ES2526191T3 - Método para producir virus influenza B infeccioso en cultivo celular - Google Patents

Método para producir virus influenza B infeccioso en cultivo celular Download PDF

Info

Publication number
ES2526191T3
ES2526191T3 ES03724208.8T ES03724208T ES2526191T3 ES 2526191 T3 ES2526191 T3 ES 2526191T3 ES 03724208 T ES03724208 T ES 03724208T ES 2526191 T3 ES2526191 T3 ES 2526191T3
Authority
ES
Spain
Prior art keywords
cell culture
infectious influenza
virus
influenza
produce infectious
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03724208.8T
Other languages
English (en)
Spanish (es)
Inventor
Erich Hoffman
Hong Jin
Bin Lu
Greg Duke
George William Kemble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Application granted granted Critical
Publication of ES2526191T3 publication Critical patent/ES2526191T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16262—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES03724208.8T 2002-04-26 2003-04-25 Método para producir virus influenza B infeccioso en cultivo celular Expired - Lifetime ES2526191T3 (es)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US37567502P 2002-04-26 2002-04-26
US375675P 2002-04-26
US39498302P 2002-07-09 2002-07-09
US394983P 2002-07-09
US41057602P 2002-09-12 2002-09-12
US410576P 2002-09-12
US41980202P 2002-10-18 2002-10-18
US419802P 2002-10-18
US42070802P 2002-10-23 2002-10-23
US420708P 2002-10-23
US45769903P 2003-03-24 2003-03-24
US457699P 2003-03-24
US46236103P 2003-04-10 2003-04-10
US462361P 2003-04-10
PCT/US2003/012728 WO2003091401A2 (en) 2002-04-26 2003-04-25 Multi plasmid system for the production of influenza virus

Publications (1)

Publication Number Publication Date
ES2526191T3 true ES2526191T3 (es) 2015-01-08

Family

ID=29273967

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03724208.8T Expired - Lifetime ES2526191T3 (es) 2002-04-26 2003-04-25 Método para producir virus influenza B infeccioso en cultivo celular

Country Status (12)

Country Link
US (3) US8012736B2 (enExample)
EP (2) EP2497826A1 (enExample)
JP (4) JP2005523698A (enExample)
KR (2) KR101229202B1 (enExample)
CN (4) CN103540613A (enExample)
AR (2) AR039465A1 (enExample)
AU (2) AU2003231083A1 (enExample)
CA (1) CA2482946C (enExample)
DK (1) DK1499348T3 (enExample)
ES (1) ES2526191T3 (enExample)
TW (2) TWI347363B (enExample)
WO (1) WO2003091401A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259211B2 (en) * 2000-04-28 2006-07-13 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
ES2356934T3 (es) 2001-06-05 2011-04-14 Curevac Gmbh ARNm ESTABILIZADO CON UN CONTENIDO DE G/C AUMENTADO QUE CODIFICA PARA UN ANTÍGENO VIRAL.
US20050158342A1 (en) * 2003-12-23 2005-07-21 Medimmune, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
AU2003231083A1 (en) 2002-04-26 2003-11-10 Medimmune, Llc Multi plasmid system for the production of influenza virus
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CA2807534A1 (en) 2003-02-25 2005-02-17 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
KR20060026854A (ko) * 2003-05-28 2006-03-24 위스콘신 얼럼나이 리서어치 화운데이션 ＰｏｌⅡ 프로모터 및 리보자임을 갖는 재조합 인플루엔자벡터
WO2005018539A2 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
HUE025727T2 (en) * 2004-05-24 2016-04-28 Medimmune Llc Multi-plasmid system for producing influenza virus
ES2393492T3 (es) * 2004-05-25 2012-12-21 Medimmune, Llc Variantes de hemaglutinina y neuraminidasa de influenza
EP1797189A4 (en) * 2004-09-02 2010-05-19 Qun Chen ENCAPSIDATION SYSTEM FOR THE PRODUCTION OF RECOMBINANT VIRUSELY PARTICLES
JP2008512443A (ja) * 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
AU2005303817B8 (en) * 2004-11-11 2010-09-30 Abbott Biologicals B.V. Defective influenza virus particles
CN101056976A (zh) * 2004-11-11 2007-10-17 索尔瓦药物有限公司 有缺陷的流感病毒颗粒
AU2005337178A1 (en) 2004-11-19 2007-04-19 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
CN102978169A (zh) 2004-12-08 2013-03-20 米迪缪尼有限公司 生产流感疫苗组合物的方法
EP1831353B1 (en) 2004-12-23 2012-02-29 MedImmune, LLC Non-tumorigenic mdck cell line for propagating viruses
KR101272487B1 (ko) * 2004-12-24 2013-06-07 에라스무스 유니버시티 메디컬 센터 로테르담 인플루엔자 바이러스의 구제
EP2471552B1 (en) 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
US7959929B2 (en) * 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1917361A4 (en) 2005-06-21 2009-07-29 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING NEGATIVE SENSE RNA VIRUS IN CANINE CELLS
JP5349049B2 (ja) 2005-10-17 2013-11-20 メディミューン，エルエルシー インフルエンザウイルス製造用マルチプラスミド系
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
US20070197460A1 (en) * 2005-11-01 2007-08-23 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
AU2007245192B2 (en) * 2006-03-31 2012-04-12 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
DK2016194T3 (en) * 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
US9072701B2 (en) 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
US7507411B2 (en) * 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
EP2049662A4 (en) * 2006-07-21 2009-12-30 Medimmune Llc METHODS AND COMPOSITIONS FOR INCREASING REPLICATION CAPACITY OF A FLU VIRUS
JP2010500034A (ja) * 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
KR101464783B1 (ko) 2006-09-15 2014-11-26 메디뮨 엘엘씨 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정
CA2690196A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2045323A1 (en) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
US9592285B2 (en) * 2007-11-12 2017-03-14 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of influenza virus
CN102149405A (zh) * 2008-07-11 2011-08-10 米迪缪尼股份有限公司 流感血凝素和神经氨酸酶变体
CA2738024A1 (en) 2008-09-24 2010-04-01 Medimmune, Llc Methods for purification of viruses
WO2010046335A1 (en) * 2008-10-21 2010-04-29 Crucell Holland B.V. Production of influenza virus by reverse genetics in per.c6 cells under serum free conditions
AU2009333208A1 (en) 2008-12-16 2010-07-08 Baxter Healthcare Sa Production of influenza vaccines
EP2233152A1 (en) * 2009-03-24 2010-09-29 Avir Green Hills Biotechnology Research Development Trade Ag High growth reassortant influenza A virus
CN102361649A (zh) * 2009-02-12 2012-02-22 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
EP2491117B2 (en) * 2009-10-20 2017-06-28 Novartis AG Improved reverse genetics methods for virus rescue
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
CN102741428A (zh) * 2009-11-16 2012-10-17 基因特力株式会社 基因分型的方法
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
KR101323582B1 (ko) * 2011-03-17 2013-10-30 충북대학교 산학협력단 Ｖｅｒｏ 세포 유래의 ｐｏｌⅠ 프로모터 및 이를 포함하는 재조합 벡터
US20130189303A1 (en) * 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
CN102864130A (zh) * 2011-09-08 2013-01-09 中国农业科学院上海兽医研究所 高效表达ha蛋白的重组流感病毒及其制备方法和应用
CN102864127A (zh) * 2011-09-08 2013-01-09 中国农业科学院上海兽医研究所 高效表达ha蛋白的重组流感病毒及其制备方法和应用
CN102851258A (zh) * 2011-09-08 2013-01-02 中国农业科学院上海兽医研究所 高效表达ha蛋白的重组流感病毒及其制备方法和应用
HK1200845A1 (en) 2011-10-07 2015-08-14 Medimmune, Llc Influenza hemagglutinin variants
WO2013177595A2 (en) * 2012-05-25 2013-11-28 University Of Maryland Recombinant influenza viruses and constructs and uses thereof
KR101443983B1 (ko) * 2012-12-04 2014-11-03 충북대학교 산학협력단 Mdck 세포 특이적으로 증식성이 향상된 다중 돌연변이 인플루엔자 a 바이러스
FR3004726A1 (fr) 2013-04-18 2014-10-24 Agronomique Inst Nat Rech Mutants thermosensibles de virus influenza
EP3022296B1 (en) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
CN105518129B (zh) * 2013-07-19 2020-04-28 罗切斯特大学 减毒流感疫苗和其用途
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN104450695B (zh) * 2014-11-26 2017-08-25 扬州大学 A型流感病毒基因pcr扩增引物及其快速克隆方法
CN104592367B (zh) * 2014-12-24 2019-01-18 中国科学院微生物研究所 流感病毒np蛋白突变体及其编码基因与应用
US10323231B2 (en) 2015-04-24 2019-06-18 University Of Rochester Attenuated influenza vaccines and uses thereof
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
WO2018013704A1 (en) 2016-07-12 2018-01-18 Duke University Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same
EP3700562A1 (en) 2017-10-25 2020-09-02 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
MX2020006530A (es) 2017-12-22 2020-10-15 Codagenix Inc Virus recombinante con region desoptimizada de par de codones y usos del mismo para el tratamiento de cancer.
CA3091508A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
EP3840780A1 (en) 2018-08-20 2021-06-30 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
CN111363017B (zh) * 2018-12-25 2022-03-15 中国科学院微生物研究所 A型流感病毒核蛋白s69位突变序列及其突变体与应用
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
US12419946B2 (en) 2019-02-07 2025-09-23 Duke University Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US11214799B2 (en) * 2019-03-12 2022-01-04 The University Court Of The University Of Edinburg Old College HA-specific influenza virus attenuated vaccine comprising mutations in segment 7, and uses therefor
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CN110713988A (zh) * 2019-05-13 2020-01-21 广州医科大学附属第一医院（广州呼吸中心） 一种防止接种于鸡蛋的季节性人流感h3n2病毒抗原性降低的方法
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN117946982B (zh) * 2022-12-30 2025-06-03 中国科学院微生物研究所 H1n1流感病毒冷适应疫苗骨架毒株cv1-pr8及其构建方法和应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB660109A (en) 1946-10-01 1951-10-31 American Cyanamid Co Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine
US3992522A (en) 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
US3874999A (en) 1973-10-31 1975-04-01 American Cyanamid Co Process for the purification of virus vaccine
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
US4000257A (en) 1975-12-22 1976-12-28 American Cyanamid Company Process for the purification of influenza virus vaccine
US4057626A (en) 1976-10-08 1977-11-08 Richardson-Merrell Inc. Process for detoxifying influenza B virus
US4338296A (en) 1979-10-16 1982-07-06 Smithkline-Rit Influenza virus and process of producing a vaccine therefrom
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4512972A (en) 1980-06-30 1985-04-23 Kureha Chemical Industry Co., Ltd. Nasal preparation and processes for their production
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4512285A (en) 1983-12-27 1985-04-23 Gof Manufacturing Company, Inc. Apparatus and method for egg turning during incubation
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
GB8914968D0 (en) 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
WO1993021306A1 (en) 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Genetically engineered attenuated viruses
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AU2088992A (en) 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
ES2210273T5 (es) 1994-07-18 2010-03-29 Conzelmann, Karl-Klaus, Prof. Dr. Virus con arn de cadena negativa no segmentado recombinante infeccioso.
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5716821A (en) 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
WO1996010400A1 (en) 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
WO1996010633A1 (en) 1994-09-30 1996-04-11 Aviron Chimeric influenza virus and electroporation method
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0865296B1 (en) 1995-10-20 2002-02-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Influenza vaccine
ATE298789T1 (de) 1995-10-31 2005-07-15 Dnavec Research Inc Negativstrand rna virus mit selbständiger replikationsaktivität
DK0863202T3 (da) 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
US6090391A (en) 1996-02-23 2000-07-18 Aviron Recombinant tryptophan mutants of influenza
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6146872A (en) * 1996-06-13 2000-11-14 Fukisawa Pharmaceutical Co., Ltd. Cyclic lipopeptide acylase
WO1998002530A1 (en) 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
JP2000517194A (ja) 1996-09-27 2000-12-26 アメリカン・サイアナミド・カンパニー モノネガビラレス（Ｍｏｎｏｎｅｇａｖｉｒａｌｅｓ）と称される目のウイルスにおける弱毒化の原因となる３’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異
CN1250725C (zh) 1997-05-23 2006-04-12 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法
DE69837764T2 (de) 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
CA2302867A1 (en) 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6492427B2 (en) * 1998-10-09 2002-12-10 L. Sai Latha Shankar Methods for treating multiple sclerosis
EP1035209A1 (en) 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
CA2365526C (en) * 1999-04-06 2016-07-05 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU2001250352B2 (en) 2000-03-02 2006-01-12 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza a viruses
AU2001259211B2 (en) * 2000-04-28 2006-07-13 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
CN1582333B (zh) 2000-09-25 2010-06-16 波利门科学生物免疫研究有限公司 活疫苗及生产方法
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
US20050158342A1 (en) 2003-12-23 2005-07-21 Medimmune, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
AU2003231083A1 (en) 2002-04-26 2003-11-10 Medimmune, Llc Multi plasmid system for the production of influenza virus
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CA2807534A1 (en) 2003-02-25 2005-02-17 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
HUE025727T2 (en) 2004-05-24 2016-04-28 Medimmune Llc Multi-plasmid system for producing influenza virus
CA2583698C (en) 2004-10-06 2014-12-02 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
WO2006049061A1 (ja) 2004-11-01 2006-05-11 Eiken Kagaku Kabushiki Kaisha Ｈ５型又はｈ７型トリインフルエンザウイルスの検出方法
CA2690196A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
MX2010008861A (es) * 2008-02-15 2011-02-22 Sun Pharma Advanced Res Co Ltd Tableta oral de liberacion controlada con efecto de liberacion masiva reducido.

Also Published As

Publication number Publication date
KR101169468B1 (ko) 2012-08-01
AR039465A1 (es) 2005-02-23
AU2009225296A1 (en) 2009-10-29
TWI338047B (en) 2011-03-01
CN1678345A (zh) 2005-10-05
US8012736B2 (en) 2011-09-06
HK1082422A1 (en) 2006-06-09
JP2005523698A (ja) 2005-08-11
TWI347363B (en) 2011-08-21
JP2013179943A (ja) 2013-09-12
CN103540568A (zh) 2014-01-29
TW201107476A (en) 2011-03-01
JP5303603B2 (ja) 2013-10-02
WO2003091401A2 (en) 2003-11-06
CN103540613A (zh) 2014-01-29
AU2009225296B2 (en) 2012-01-12
DK1499348T3 (en) 2015-01-05
KR20050000408A (ko) 2005-01-03
EP2497826A1 (en) 2012-09-12
WO2003091401A3 (en) 2004-03-25
US20040029251A1 (en) 2004-02-12
JP2011217748A (ja) 2011-11-04
CN1678345B (zh) 2013-09-11
CA2482946C (en) 2013-09-17
KR101229202B1 (ko) 2013-02-01
EP1499348B1 (en) 2014-10-01
JP2013230156A (ja) 2013-11-14
TW200409819A (en) 2004-06-16
US20120020997A1 (en) 2012-01-26
AR081941A2 (es) 2012-10-31
KR20110059911A (ko) 2011-06-07
US20140220075A1 (en) 2014-08-07
AU2003231083A1 (en) 2003-11-10
EP1499348A2 (en) 2005-01-26
US8722059B2 (en) 2014-05-13
CA2482946A1 (en) 2003-11-06
EP1499348A4 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
ES2526191T3 (es) Método para producir virus influenza B infeccioso en cultivo celular
ATE353370T1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
Kingsbury The molecular biology of paramyxoviruses
EP1697521A4 (en) PLASMID MULTIPLE SYSTEM FOR PRODUCING INFLUENZA VIRUS
MXPA05009096A (es) Metodo de cultivo celular libre de animal.
BRPI0612268A2 (pt) Ácido nucleico isolado, vetor de expressço, mÉtodos para produzir um rna genâmico da influenza, para produzir um vÍrus da influenza recombinante, para gerar um vÍrus de rna segmentado de filamento negativo recombinante nas cÉlulas caninas cultivadas e para gerar partÍculas virais da influenza infecciosa em cÉlulas caninas cultivadas, cÉlula, e, vÍrus
DK1170376T3 (da) Fremgangsmåde til fremstilling af L-aminosyre eller nukleinsyre ved anvendelse af mikroorganisme
CY1114598T1 (el) Μεθοδος για την ενισχυση ενος ιου φυσαλιδωδους νοσου υπο συνθηκες ελευθερες ορου
CA2851807A1 (en) Nucleic acid construct containing full length genome of human hepatitis c virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis c virus particle
ATE452187T1 (de) Methode zur isolation von nukleinsäuren
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
ES2570665T3 (es) Factor de permisividad celular para virus, y usos del mismo
EP1721981A4 (en) RECOMBINANT VARICELLA ZOSTER VIRUS
HRP20090230T1 (hr) Replikacijski-defektni rna virusi kao cjepiva
WO2006038129A3 (en) Hepatitis c virus replication system
CN108913684A (zh) 一种外源片段高效定点定向插入dna病毒基因组的方法
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a
CN108486115A (zh) 一种用于淡水螯虾细胞外源基因表达的转染方法及其应用
EP1666598A4 (en) NUCLEIC ACID AND GEN GENES FROM A NEW HCV TRIBE, AND THE REPLICANT-REPLICATING CELL USING THE GENE
WO2001090302A3 (en) Compositions and methods for production of rna viruses and rna virus-based vector particles
Liu et al. Multiple levels of triggered factors and positive effect of cell-to-cell bottleneck in mutation repair of RNA viruses
US11173200B2 (en) Phenotypically wild-type and genetically attenuated viruses
WO2002061048A3 (en) In vitro system for replication of rna-dependent rna polymerase (rdrp) viruses
CN116804210A (zh) 一种肠道病毒载体及其应用
ES8703519A1 (es) Procedimiento para la formacion de hibridos celulares